Breaking News Instant updates and real-time market news.

RHHBY

Roche

$28.20

-0.08 (-0.28%)

13:05
12/22/16
12/22
13:05
12/22/16
13:05

Genentech's emicizumab meets primary endpoint in Phase III study

Genentech, a member of the Roche Group, announced that the primary endpoint has been met for the Phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or older with hemophilia A and inhibitors to factor VIII. The study showed a statistically significant reduction in the number of bleeds over time in people treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. The study also met all secondary endpoints, including a statistically significant reduction in the number of bleeds over time with emicizumab prophylaxis treatment in an intra-patient comparison in people who had received prior bypassing agent prophylaxis treatment. The most common adverse events with emicizumab were injection site reactions, consistent with prior studies. As previously reported, two patients had thromboembolic events and two patients developed thrombotic microangiopathy. The common aspect between all cases of thromboembolic events and TMA is that they occurred in patients who were on emicizumab prophylaxis and in addition received activated prothrombin complex concentrate to treat breakthrough bleeds. Neither thromboembolic event required anti-coagulation therapy and one patient restarted emicizumab. Both cases of TMA have completely resolved, and one patient restarted emicizumab. HAVEN 1 is the first Phase III study in the emicizumab clinical development program to report results. Data from the study will be presented at an upcoming medical meeting and submitted to health authorities around the world for approval consideration.

  • 01

    Feb

  • 21

    Feb

RHHBY Roche
$28.20

-0.08 (-0.28%)

12/15/16
CANT
12/15/16
NO CHANGE
Target $15
CANT
Overweight
Cantor says Roche deal termination significant negative for Pacific Biosciences
Cantor Fitzgerald analyst Bryan Brokmeier said Roche's (RHHBY) termination of its collaboration agreement with Pacific Biosciences is a "significant negative" for the latter, as he was forecasting Roche-generated revenues of $14.3M in 2017 and $27.5M in 2018. Pacific Bio should not lose all of that revenue, since it will now be able to sell into the clinical market or partner with another company, but that will require further investments, said Brokmeier, who has an Overweight rating and $15 price target on the stock.
12/15/16
PIPR
12/15/16
NO CHANGE
Target $6
PIPR
Neutral
Pacific Biosciences price target lowered to $6 from $10 at Piper Jaffray
Piper Jaffray analyst William Quirk lowered his price target for Pacific Biosciences (PACB) to $6 from $10 after Roche (RHHBY) terminated its Sequel system contract with the company. Pacific Biosciences believes Roche's decision stems from a change in the sequencing market dynamics, the analyst notes, adding that Roche said "somewhat vaguely" that Sequel can no longer meet a list of requirements the company established. Additionally, Quirk believes the mid-point of Pacific Biosciences' 2017 guidance may be difficult to reach, and reiterates a Neutral rating on the shares.
12/15/16
CANT
12/15/16
NO CHANGE
Target $8
CANT
Overweight
Pacific Biosciences a 'viable takeout target,' says Cantor
Cantor analyst Bryan Brokmeier says Pacific Biosciences' (PACB) shares are oversold after the company announced that Roche (RHHBY) has terminated their IVD-distribution agreement, whereby Roche had exclusive distribution rights of the Sequel into the clinical market. While the analyst acknowledges Roche's termination of the agreement is a clear long-term strategic negative, he says it is not nearly as much as the stock selloff is implying and notes that Pacific Biosciences is now positioned to sell into the clinical sequencing market directly or through other partners. Moreover, Brokmeier believes Pacific Biosciences is now "effectively a viable takeout target" for other companies, with Agilent (A), Bio-Techne (TECH), Illumina (ILMN), PerkinElmer (PKI), Thermo Fisher (TMO), and Roche among potential acquirers. He reiterated an Overweight rating on Pacific Biosciences' stock, but lowered his price target on the shares to $8 from $15.
12/19/16
JEFF
12/19/16
DOWNGRADE
Target $48
JEFF
Underperform
Merck downgraded to Underperform from Hold at Jefferies
Jefferies analyst Jeffrey Holford downgraded Merck (MRK) to Underperform, his firm's sell-rating equivalent. The analyst sees Pharmaceutical sector fundamentals weakening in 2017 amid political overhangs and an adverse macro environment. Potential dual eligible rebate reform is the most significant risk, Holford tells investors in a research note. Specific to Merck, the analyst expects further pressure on Keytruda in 2018, driven by share losses in non-small cell lung cancer to Bristol-Myers Squibb (BMY), AstraZeneca (AZN) and Roche (RHHBY). Merck screens poorly on many valuation metrics, Holford contends. He lowered his price target for the shares to $48 from $59. The stock closed Friday up 7c to $62.44. The analyst this morning also upgraded both Bristol-Myers Squibb (BMY) and Bayer (BAYRY) to Buy from Hold. His top picks in Pharmaceuticals are AbbVie (ABBV) and Eli Lilly (LLY) for the U.S. and AstraZeneca and Novartis (NVS) in Europe.

TODAY'S FREE FLY STORIES

CPN

Calpine

$14.87

1.365 (10.11%)

12:20
08/18/17
08/18
12:20
08/18/17
12:20
Options
Heavy trading in Calpine calls as shares rally »

Heavy trading in Calpine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$19.55

-0.07 (-0.36%)

12:19
08/18/17
08/18
12:19
08/18/17
12:19
Hot Stocks
U.S EEOC sues Macy's for disability discrimination »

The U.S. Equal Employment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

$NSD

NASDAQ Market Internals

12:17
08/18/17
08/18
12:17
08/18/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
08/18/17
08/18
12:16
08/18/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$62.36

0.35 (0.56%)

, XLU

Utilities SPDR

$54.48

0.3 (0.55%)

12:06
08/18/17
08/18
12:06
08/18/17
12:06
Technical Analysis
Technical View: S&P 500 edges above flatline, mid-session update »

The S&P 500 (SPX) was…

XLE

Energy Select Sector SPDR

$62.36

0.35 (0.56%)

XLU

Utilities SPDR

$54.48

0.3 (0.55%)

XLF

Financial Select Sector

$24.72

0.105 (0.43%)

XLK

Technology Select Sector SPDR

$57.33

0.2 (0.35%)

IYR

DJ US Real Estate Index Fund

$79.07

-0.7 (-0.88%)

XLP

Consumer Staples Sector SPDR

$55.25

-0.105 (-0.19%)

XLY

Consumer Discretionary Sector SPDR

$88.62

-0.07 (-0.08%)

SPY

SPDR S&P 500 ETF Trust

$243.52

0.43 (0.18%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$910.98

-15.98 (-1.72%)

, GOOGL

Alphabet Class A

$927.66

-16.61 (-1.76%)

12:04
08/18/17
08/18
12:04
08/18/17
12:04
Hot Stocks
Google launches new machine learning tool to track hate news »

In a blog post…

GOOG

Alphabet

$910.98

-15.98 (-1.72%)

GOOGL

Alphabet Class A

$927.66

-16.61 (-1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 24

    Aug

FMAO

Farmers & Merchants

$55.58

-0.17 (-0.30%)

12:00
08/18/17
08/18
12:00
08/18/17
12:00
Hot Stocks
Farmers & Merchants board declares two-for-one stock split »

Farmers & Merchants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$117.19

-6.7905 (-5.48%)

, CPN

Calpine

$14.83

1.33 (9.85%)

12:00
08/18/17
08/18
12:00
08/18/17
12:00
General news
On The Fly: Top stock stories at midday »

Stocks opened in negative…

DE

Deere

$117.19

-6.7905 (-5.48%)

CPN

Calpine

$14.83

1.33 (9.85%)

GPS

Gap

$22.43

-0.255 (-1.12%)

ROST

Ross Stores

$53.33

-1.04 (-1.91%)

AMAT

Applied Materials

$43.12

-1.34 (-3.01%)

THC

Tenet

$14.04

1.385 (10.95%)

INFY

Infosys

$14.71

-1.22 (-7.66%)

FL

Foot Locker

$34.97

-12.73 (-26.69%)

FINL

Finish Line

$11.99

-0.17 (-1.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 18

    Aug

  • 23

    Aug

  • 06

    Sep

  • 06

    Sep

  • 22

    Nov

BC

Brunswick

$50.33

-0.995 (-1.94%)

12:00
08/18/17
08/18
12:00
08/18/17
12:00
Options
Call buyers in Brunswick as shares fall »

Call buyers in Brunswick…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

FL

Foot Locker

$34.98

-12.7201 (-26.67%)

11:59
08/18/17
08/18
11:59
08/18/17
11:59
Downgrade
Foot Locker rating change  »

Foot Locker downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

RDUS

Radius Health

$35.42

-1.01 (-2.77%)

11:58
08/18/17
08/18
11:58
08/18/17
11:58
Hot Stocks
Biotech Growth acquires 60,000 more shares of Radius Health »

Biotech Growth NV…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

CVNA

Carvana

$15.12

-0.06 (-0.40%)

11:54
08/18/17
08/18
11:54
08/18/17
11:54
Hot Stocks
Breaking Hot Stocks news story on Carvana »

Carvana drops 3% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 06

    Sep

  • 12

    Sep

CVNA

Carvana

$15.12

-0.06 (-0.40%)

11:53
08/18/17
08/18
11:53
08/18/17
11:53
Periodicals
Carvana mentioned cautiously by Copperfield Research »

Copperfield Research, in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 06

    Sep

  • 12

    Sep

AMAT

Applied Materials

$43.12

-1.34 (-3.01%)

11:51
08/18/17
08/18
11:51
08/18/17
11:51
Hot Stocks
Applied Materials CEO says technological shifts in industries to drive growth »

The CEO says has a good…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$34.76

-12.94 (-27.13%)

11:50
08/18/17
08/18
11:50
08/18/17
11:50
Recommendations
Foot Locker analyst commentary  »

Foot Locker comp outlook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

11:50
08/18/17
08/18
11:50
08/18/17
11:50
General news
Fed's Kaplan sees GDP growth a little above 2% for 2017 »

Fed's Kaplan sees…

AMZN

Amazon.com

$960.57

-17.61 (-1.80%)

, ATVI

Activision Blizzard

$61.37

-1.52 (-2.42%)

11:49
08/18/17
08/18
11:49
08/18/17
11:49
Periodicals
Twitch acquires video indexing platform Clipmine, TechCrunch reports »

Twitch has acquired video…

AMZN

Amazon.com

$960.57

-17.61 (-1.80%)

ATVI

Activision Blizzard

$61.37

-1.52 (-2.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 23

    Aug

  • 24

    Aug

  • 24

    Aug

  • 05

    Sep

  • 07

    Sep

FL

Foot Locker

$34.82

-12.88 (-27.00%)

11:45
08/18/17
08/18
11:45
08/18/17
11:45
Downgrade
Foot Locker rating change  »

Wells doubts investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

AMAT

Applied Materials

$43.12

-1.34 (-3.01%)

11:42
08/18/17
08/18
11:42
08/18/17
11:42
Hot Stocks
Applied Materials CEO says much less volatility in chip sector »

The Applied Materials CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$34.94

-12.76 (-26.75%)

, NKE

Nike

$55.19

-2.27 (-3.95%)

11:41
08/18/17
08/18
11:41
08/18/17
11:41
Recommendations
Foot Locker, Nike, adidas analyst commentary  »

Foot Locker price target…

FL

Foot Locker

$34.94

-12.76 (-26.75%)

NKE

Nike

$55.19

-2.27 (-3.95%)

ADDYY

adidas

$111.98

-1.52 (-1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 03

    Oct

  • 04

    Oct

NBL

Noble Energy

$23.44

0.415 (1.80%)

11:40
08/18/17
08/18
11:40
08/18/17
11:40
Options
Notable put spread in Noble Energy »

Notable put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

ABCO

The Advisory Board

$51.05

-0.8 (-1.54%)

11:35
08/18/17
08/18
11:35
08/18/17
11:35
Options
Advisory Board put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTNB

root9B Technologies

$0.60

-0.1665 (-21.72%)

11:30
08/18/17
08/18
11:30
08/18/17
11:30
Hot Stocks
Breaking Hot Stocks news story on root9B Technologies »

root9B Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNGA

Magnegas

$0.49

0.013139 (2.76%)

11:25
08/18/17
08/18
11:25
08/18/17
11:25
Conference/Events
Magnegas to host business news update conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Aug

URBN

Urban Outfitters

$18.94

-0.82 (-4.15%)

11:20
08/18/17
08/18
11:20
08/18/17
11:20
Options
Urban Outfitters Sep 15 puts trade more than 90K »

Urban Outfitters Sep 15…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.